These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 27000940)
1. Amygdala Hyperactivity in MAM Model of Schizophrenia is Normalized by Peripubertal Diazepam Administration. Du Y; Grace AA Neuropsychopharmacology; 2016 Sep; 41(10):2455-62. PubMed ID: 27000940 [TBL] [Abstract][Full Text] [Related]
2. Peripubertal diazepam administration prevents the emergence of dopamine system hyperresponsivity in the MAM developmental disruption model of schizophrenia. Du Y; Grace AA Neuropsychopharmacology; 2013 Sep; 38(10):1881-8. PubMed ID: 23612434 [TBL] [Abstract][Full Text] [Related]
3. Loss of Parvalbumin in the Hippocampus of MAM Schizophrenia Model Rats Is Attenuated by Peripubertal Diazepam. Du Y; Grace AA Int J Neuropsychopharmacol; 2016 Nov; 19(11):. PubMed ID: 27432008 [TBL] [Abstract][Full Text] [Related]
4. Afferent drive of medial prefrontal cortex by hippocampus and amygdala is altered in MAM-treated rats: evidence for interneuron dysfunction. Esmaeili B; Grace AA Neuropsychopharmacology; 2013 Sep; 38(10):1871-80. PubMed ID: 23471079 [TBL] [Abstract][Full Text] [Related]
5. Impaired contextual fear-conditioning in MAM rodent model of schizophrenia. Gill KM; Miller SA; Grace AA Schizophr Res; 2018 May; 195():343-352. PubMed ID: 28927551 [TBL] [Abstract][Full Text] [Related]
6. Aberrant high frequency oscillations recorded in the rat nucleus accumbens in the methylazoxymethanol acetate neurodevelopmental model of schizophrenia. Goda SA; Olszewski M; Piasecka J; Rejniak K; Whittington MA; Kasicki S; Hunt MJ Prog Neuropsychopharmacol Biol Psychiatry; 2015 Aug; 61():44-51. PubMed ID: 25862088 [TBL] [Abstract][Full Text] [Related]
7. Role of the prefrontal cortex in altered hippocampal-accumbens synaptic plasticity in a developmental animal model of schizophrenia. Belujon P; Patton MH; Grace AA Cereb Cortex; 2014 Apr; 24(4):968-77. PubMed ID: 23236209 [TBL] [Abstract][Full Text] [Related]
9. The methylazoxymethanol acetate rat model: molecular and epigenetic effect in the developing prefrontal cortex: An Editorial Highlight for 'Epigenetic mechanisms underlying NMDA receptor hypofunction in the prefrontal cortex of juvenile animals in the MAM model for schizophrenia' on page 320. Zhu X; Gomes FV; Grace AA J Neurochem; 2017 Nov; 143(3):264-267. PubMed ID: 28872674 [TBL] [Abstract][Full Text] [Related]
10. Biochemical and cognitive impairments observed in animal models of schizophrenia induced by prenatal stress paradigm or methylazoxymethanol acetate administration. Ratajczak P; Kus K; Murawiecka P; Słodzińska I; Giermaziak W; Nowakowska E Acta Neurobiol Exp (Wars); 2015; 75(3):314-25. PubMed ID: 26581387 [TBL] [Abstract][Full Text] [Related]
11. Fear extinction disruption in a developmental rodent model of schizophrenia correlates with an impairment in basolateral amygdala-medial prefrontal cortex plasticity. Uliana DL; Resstel LBM; Grace AA Neuropsychopharmacology; 2018 Nov; 43(12):2459-2467. PubMed ID: 29973655 [TBL] [Abstract][Full Text] [Related]
12. A neurobehavioral systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: implications for the neuropathology of schizophrenia. Moore H; Jentsch JD; Ghajarnia M; Geyer MA; Grace AA Biol Psychiatry; 2006 Aug; 60(3):253-64. PubMed ID: 16581031 [TBL] [Abstract][Full Text] [Related]
13. Structural abnormalities revealed by magnetic resonance imaging in rats prenatally exposed to methylazoxymethanol acetate parallel cerebral pathology in schizophrenia. Chin CL; Curzon P; Schwartz AJ; O'Connor EM; Rueter LE; Fox GB; Day M; Basso AM Synapse; 2011 May; 65(5):393-403. PubMed ID: 20803618 [TBL] [Abstract][Full Text] [Related]
14. Decrease in parvalbumin-expressing neurons in the hippocampus and increased phencyclidine-induced locomotor activity in the rat methylazoxymethanol (MAM) model of schizophrenia. Penschuck S; Flagstad P; Didriksen M; Leist M; Michael-Titus AT Eur J Neurosci; 2006 Jan; 23(1):279-84. PubMed ID: 16420437 [TBL] [Abstract][Full Text] [Related]
15. Peripubertal mGluR2/3 Agonist Treatment Prevents Hippocampal Dysfunction and Dopamine System Hyperactivity in Adulthood in MAM Model of Schizophrenia. Sonnenschein SF; Grace AA Schizophr Bull; 2021 Oct; 47(6):1806-1814. PubMed ID: 33928393 [TBL] [Abstract][Full Text] [Related]
16. Development of the MAM model of schizophrenia in mice: Sex similarities and differences of hippocampal and prefrontal cortical function. Chalkiadaki K; Velli A; Kyriazidis E; Stavroulaki V; Vouvoutsis V; Chatzaki E; Aivaliotis M; Sidiropoulou K Neuropharmacology; 2019 Jan; 144():193-207. PubMed ID: 30366002 [TBL] [Abstract][Full Text] [Related]
18. The MAM-E17 schizophrenia rat model: Comprehensive behavioral analysis of pre-pubertal, pubertal and adult rats. Kállai V; Tóth A; Gálosi R; Péczely L; Ollmann T; Petykó Z; László K; Kállai J; Szabó I; Karádi Z; Lénárd L Behav Brain Res; 2017 Aug; 332():75-83. PubMed ID: 28577920 [TBL] [Abstract][Full Text] [Related]
19. A novel α5GABA(A)R-positive allosteric modulator reverses hyperactivation of the dopamine system in the MAM model of schizophrenia. Gill KM; Lodge DJ; Cook JM; Aras S; Grace AA Neuropsychopharmacology; 2011 Aug; 36(9):1903-11. PubMed ID: 21562483 [TBL] [Abstract][Full Text] [Related]
20. Prenatal disruption of neocortical development alters prefrontal cortical neuron responses to dopamine in adult rats. Lavin A; Moore HM; Grace AA Neuropsychopharmacology; 2005 Aug; 30(8):1426-35. PubMed ID: 15827574 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]